Ignite Creation Date:
2024-05-05 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00529503
Status:
TERMINATED
Last Update Posted:
2015-02-25
First Post:
2007-09-11
Brief Title:
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
Sponsor:
Seagen Inc
Organization:
Seagen Inc
Study Overview
Official Title:
A Randomized Phase IIb Placebo-controlled Study of R-ICE Chemotherapy With and Without SGN-40 Anti-CD40 Humanized Monoclonal Antibody for Second-line Treatment of Patients With Diffuse Large B-Cell Lymphoma DLBCL
Status:
TERMINATED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs R-ICE plus placebo in patients with DLBCL The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None